USPTO serial 79228430
NICTUR
Reviewed by CopyMark Law Group
Reg. 5663531Status 709
- Filing date
- Status date
- Registration date
- Jan 29, 2019
- Examiner
- DAWE III, WILLIAM H
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with NICTUR?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
SantQuinti de Mediona (Barcelona), ES
SantQuinti de Mediona (Barcelona), ES
SantQuinti de Mediona (Barcelona), ES
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Elizabeth Lee
Elizabeth Lee Lucas & Mercanti, LLP30 Broad St., 21st FloorNew York, NY 10004UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for human use for treating nighttime or daytime enuresis, primary nocturnal enuresis, nocturia, Von Willebrand-Jurgens disease, hemorrhaging, bleeding in patients with Hemophilia A, postoperative bleeding and diabetes insipidus, for the management of surgical hemostasis, for use in renal concentrating capacity test, for use in oncology, for treating cancer, for treating cardiovascular diseases, for use as antivirals, for treating inflammatory diseases and disorders of the intestine, for treating inflammatory diseases and disorders of the connective tissue, for treating arthritis, for treating urological diseases and disorders, for treating hormonal diseases and disorders, for treating endocrinological diseases and disorders, for treating psychiatric diseases and disorders, in particular mood disorders, anxiety disorders, cognitive disorders and schizophrenia, for treating neurological and neurodegenerative diseases and disorders, in particular, dementia linked to Alzheimer's disease, Huntington's disease, Parkinson's disease, cerebral palsy, brain injuries and diseases, injuries and diseases of the spinal cord, convulsive disorders, epilepsy, encephalitis, disorders of the central nervous system, ocular motility disorders, dystonia, blepharospasm, strabismus, facial scoliosis and tics, cerebral ischemia, dementia, amyotrophic sclerosis, and lateral multiple sclerosis, for treating auto-immune diseases and disorders, for treating transplant rejection, for treating ophthalmological diseases and disorders such as proliferative or non-proliferative diabetic retinopathy, macular degeneration, age-related macular degeneration, retinal neovascularization, neovascularization associated with choroidal melanoma, retinopathy, central retinal vein occlusion, pigmentary retinitis, uveitis, macular edema and cystoid macular edema; synthetic peptides for the treatment of urological, endocrine and blood diseases and disorders | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 15, 2026 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Aug 15, 2025 | C71T | CANCELLED SECTION 71 | — |
| Jan 29, 2024 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Oct 19, 2020 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Jun 7, 2019 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 22, 2019 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 21, 2019 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 29, 2019 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 25, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 25, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 29, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 23, 2018 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Nov 13, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 24, 2018 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 24, 2018 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Oct 24, 2018 | NPUB | NOTICE OF PUBLICATION | — |
| Sep 24, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 20, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 19, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 19, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 13, 2018 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 20, 2018 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 20, 2018 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 16, 2018 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 14, 2018 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 13, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 12, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 12, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 9, 2018 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Mar 8, 2018 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |